Brain tumor classification from FFPE samples using nanopore methylation sequencing
Oxford Nanopore Technology (ONT)-based methylation sequencing is emerging as a powerful approach for the rapid and accurate classification of brain tumors, an essential component of precision oncology. However, its broader clinical adoption has been limited by reliance on fresh-frozen (FF) tissue, whereas the vast majority of clinical specimens are formalin-fixed paraffin-embedded (FFPE). In this study, we address this limitation by evaluating the effects of FFPE processing on DNA methylation profiles and introducing a validated protocol for ONT-based classification using DNA extracted directly from pathology-marked regions on stained FFPE slides. This approach enables the targeted selection of tumor-rich areas following histological assessment, thereby improving DNA input quality and tumor content. We demonstrate that even small, low-input samples (≥25 ng) can be successfully classified using this method, with high concordance to final integrated neuropathological diagnoses. Our results show that, despite modest methylation loss associated with formalin fixation, classification performance remains robust. Notably, we identify a correlation between methylation degradation and fixation time, supporting a recommendation to limit formalin exposure to ≤3-4 days when possible. By enabling accurate methylation-based tumor classification from routinely processed, stained FFPE tissue, our protocol integrates seamlessly into existing clinical workflows. This expands the accessibility of ONT-based diagnostics and supports informed, timely treatment decisions-even in cases with minimal tissue availability or urgent clinical need.
Authors
- Amir Kershenovich
- Nurit Gal Mark
- Michal Hameiri‐Grossman
- Osnat Konen (ORCID: https://orcid.org/0000-0002-6265-6705)
- Shai Izraeli (ORCID: https://orcid.org/0000-0002-6938-2540)
- Yehudit Birger (ORCID: https://orcid.org/0000-0002-3400-1306)
- Carlo Vermeulen (ORCID: https://orcid.org/0000-0003-0412-5313)
- Galina Feinberg‐Gorenshtein (ORCID: https://orcid.org/0009-0009-4457-3445)
- Suzanna Fichman
- Adva Levy‐Barda (ORCID: https://orcid.org/0009-0003-8782-5100)
- Jeroen de Ridder (ORCID: https://orcid.org/0000-0002-0828-3477)
- Assaf Grunwald
- Orli Michaeli (ORCID: https://orcid.org/0000-0002-6097-6457)
- Keren Shichrur
- Andrew A. Kanner (ORCID: https://orcid.org/0000-0002-0812-8573)
- Helen Toledano (ORCID: https://orcid.org/0000-0002-1476-7937)
- Yuval Ebenstein (ORCID: https://orcid.org/0000-0002-7107-7529)
- Abraham Natan
- Hanna Weiss
- Shira Amar
- Tali Siegal
- Shlomit Yust-Katz
- Elena Shinderman-Maman
Institutions
- Holon Institute of Technology (IL)
- Tel Aviv University (IL)
- Utrecht University (NL)
- Rabin Medical Center (IL)
- University Medical Center Utrecht (NL)
- Schneider Children's Medical Center (IL)
Publication Details
- Journal
- NAR Cancer
- Published
- 2025-09-28
- DOI
- https://doi.org/10.1093/narcan/zcaf038
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Israel Cancer Research Fund
- Israel Science Foundation
- Tel Aviv University
- National Institutes of Health
- National Human Genome Research Institute